Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Elsewhere, the busy earnings season continues with reports due from several notable companies such as Advanced Micro Devices, ...

A few years ago, Pfizer (NYSE: PFE) represented the ideal pharmaceutical stock investment. The company, as leader in the coronavirus vaccine and treatment market, offered a great deal of growth, and ...

CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months.

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk today and set a price target of DKK600.00. The company’s shares closed yesterday at DKK324.94. Take advantage of ...

Pfizer has escalated its fight for obesity biotech Metsera by filing suit against both Metsera and Novo Nordisk in the ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted developer of obesity drugs.

Pfizer has filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement obligations.

Trump-Xi truce talks, Nvidia’s $5T milestone, Big Tech earnings, and Musk’s $1T showdown headline a packed week.

In a rapidly changing and uncertain world, Canada's new government is focused on what we can control. We are protecting our communities and our country. We are building our economy with major projects ...